Automated Anti-Müllerian Hormone test
Anti-Müllerian hormone (AMH) has proven to be one of the most significant new markers in reproductive endocrinology in the last 10 years. The new Access AMH assay brings automation and convenience to Beckman Coulter’s established AMH tests, which include the AMH Gen II ELISA assay and the Immunotech EIA AMH/MIS assay. Access AMH is the only automated assay having excellent correlation to AMH Gen II, providing laboratories and physicians with convenient results that are consistent with current test values and published literature. Access AMH improves test accuracy by combining the proven AMH Gen II antibodies with calibrators using recombinant human AMH to provide a direct comparison to human patient samples. Assay features include convenient transition to automated testing through consistent and standardized results with Beckman Coulter’s AMH Gen II assay; improved support of fertility assessment through increased sensitivity and precision at the low end of the analytical measuring range; improved accuracy of patient results from calibrators prepared with recombinant human AMH; efficient and cost-effective results with less technician handling time and increased ease of use compared to manual assays; speed and flexibility through fully automated instrumentation; increased stability from lyophilized calibrators. The Access AMH assay has obtained CE marking and is now available on Beckman Coulter’s Access 2 immunoassay system in Europe and other select markets. The assay will be available on all Beckman Coulter immunoassay systems in Q4 of 2014. Beckman Coulter will continue to offer the AMH Gen II and IOT AMH assays along with its new automated AMH assay.
Supplier: Beckman Coulter Eurocenter
Website:
